Trasylol Pulled From the Market and Can Only be Used for Investigational Use

By September 25, 2008July 16th, 2019Dangerous Drugs

According to an announcement made by the U.S. Food and Drug Administration, Bayer’s clotting drug Trasylol will now only be available for investigational use.
To use Trasylol, a doctor must conclude that a heart surgery patient has a high risk for blood loss, no other medication will work and that the “benefits of the drug clearly outweighs the risks.”
The news was part of a May 14 statement in which the FDA also indicated that Bayer had agreed to pull the remaining stocks of Trasylol from the U.S. market.
Earlier that same day, the Bart study was published in the New England Journal of Medicine. The study concluded that heart surgery patients given Trasylol had a 53 percent higher chance of dying than patients given less expensive, comparable drugs.
Since 2006, three studies have linked Trasylol, also known as aprotinin, to an increased risk for kidney damage, stroke and death.
My law firm currently represents several Trasylol victims and their families in lawsuits against Bayer. The lawyers of Carey, Danis & Lowe are experienced in helping people injured by Trasylol. We will seek compensation for past and future medical expenses, past and future wages, pain and suffering, disability and other damages. We also represent family members in wrongful death cases.
We offer a free initial consultation for victims harmed pharmaceutical products. If you cannot make it to our office, we will come to you at the hospital or your home.